Skip to main content

Article Category

Article available in the folowing languages:

Neuronet programme releases Knowledge Base representing key information on 18 neurodegeneration research projects encompassing 386 million EUR funding

The IMI2 Neuronet programme releases Knowledge Base dashboard representing key information on 18 neurodegeneration research projects encompassing 386 million EUR of funding.


Madrid, 1 February 2021 – Today, the members of the Neuronet (Efficiently Networking European Neurodegeneration Research) programme are pleased to announce the launch of a pan-European Knowledge Base which brings together key information about the 18 projects of the Innovative Medicines Initiative (IMI) neurodegeneration (ND) portfolio. This comprehensive resource is an integral part of Neuronet’s endeavour to boost collaboration across the research portfolio by assisting in identifying gaps, multiplying the portfolio’s impact, and enhancing its visibility with related initiatives in Europe and worldwide. “The Neuronet Knowledge Base tool intends to bring the “better together” team concept to life and overcome the inherent fragmentation often found in a project-based research landscape,” said Carlos Díaz, CEO SYNAPSE and Neuronet Coordinator. Programme overview As well as providing a summary overview of the IMI neurodegeneration research programme through its interactive dashboard, the Neuronet Knowledge Base includes links to over 380 publications and more than 350 publishable deliverable reports, acting as a one-stop shop to explore the diverse projects and outputs of the programme. Knowledge Base tools An “Asset Map” gives a comprehensive view of the different assets resulting from the projects, such as genetic datasets, clinical cohorts, and data platforms. The interactive map allows users to obtain more detailed information about the specific assets of each project. Furthermore, the Knowledge Base offers access to a regulatory, health technology assessment & payer engagement Decision Tool to help researchers identify the key processes and procedures for engagement with these stakeholders at key points in the development of an asset. Staying up to date on scientific progress and activities In addition to project and programme-related information, users can also access an agenda listing key upcoming scientific conferences and view a feed with the latest project-related activities. “This newly developed platform is key in Neuronet’s effort to centralize and integrate the vast amount of knowledge generated within the ND IMI portfolio,” said Lennert Steukers, Associate Director, Clinical Scientist, Janssen Pharmaceutica NV, and Neuronet Leader. “The Knowledge Base sets the stage for future research tools to inform and shape the next generation of research and advancements in the neurodegeneration field.” The Knowledge Base can be accessed here: About the Innovative Medicines Initiative The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA. More information: Acknowledgement This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under Grant Agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK. Disclaimer This communication reflects the views of the NEURONET Consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. Contact for further information.


Alzheimer, Dementia, Neurodegeneration, Coordination and Support Action, Parkinson, Research, Public-private collaboration, Public-private partnerships